Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282802 | 0.91 | RXFP1 (0.69) | RXFP1USP2APOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL3704786 | 0.88 | RXFP1 (0.67) | RXFP1USP2APOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL1720133 | 0.84 | RXFP1 (0.71) | RXFP1USP2APOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL1719430 | 0.84 | RXFP1 (0.72) | RXFP1USP2APOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL1719378 | 0.83 | USP2 (0.64) | RXFP1USP2APOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL1718538 | 0.83 | RXFP1 (0.68) | RXFP1USP2APOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL1719295 | 0.82 | RXFP1 (0.65) | RXFP1USP2APOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL5658010 | 0.82 | RXFP1 (0.59) | RXFP1APOBEC3ACTDSP1APOBEC3GPOLB | |
| SCHEMBL1718558 | 0.82 | RXFP1 (0.76) | RXFP1USP2APOBEC3ACTDSP1APOBEC3G | |
| SCHEMBL1717682 | 0.82 | RXFP1 (0.67) | RXFP1USP2APOBEC3ACTDSP1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | RXFP1 4572/4885USP2 1803/4885APOBEC3A 1674/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | RXFP1 4572/4885USP2 1803/4885APOBEC3A 1674/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | RXFP1 4572/4885USP2 1803/4885APOBEC3A 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.